These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11463023)

  • 1. Recombinant human activated protein C for severe sepsis.
    Ott A; Verbrugh HA
    N Engl J Med; 2001 Jul; 345(3):220; author reply 220-1. PubMed ID: 11463023
    [No Abstract]   [Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) for severe sepsis.
    Maglio D
    Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant human activated protein C for severe sepsis.
    Kapur S; Kupfer Y; Tessler S
    N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human activated protein C for severe sepsis.
    Greisman SE; Johnston CA; Gosnell MS
    N Engl J Med; 2001 Jul; 345(3):219; author reply 220-1. PubMed ID: 11463022
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant human activated protein C for severe sepsis.
    O'Connor PE
    N Engl J Med; 2001 Jul; 345(3):220; author reply 220-1. PubMed ID: 11463024
    [No Abstract]   [Full Text] [Related]  

  • 6. Drotrecogin Alfa (Activated): From Bench to Practical Use at the Bedside. Proceedings of meetings of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Clinical Evaluation Committee.
    Am J Surg; 2002 Dec; 184(6A Suppl):1S-49S. PubMed ID: 12521610
    [No Abstract]   [Full Text] [Related]  

  • 7. Breakthrough found in treatment of severe sepsis.
    Clin Resour Manag; 2001 Jul; 2(7):107-9. PubMed ID: 11482248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe sepsis.
    Bernard G
    Am J Surg; 2002 Dec; 184(6A Suppl):S3-4. PubMed ID: 12521611
    [No Abstract]   [Full Text] [Related]  

  • 9. [PROWESS--milestone in lowering sepsis mortality].
    Reinhart K
    Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
    Dhainaut JF
    Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
    Powers J; Jacobi J
    Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186
    [No Abstract]   [Full Text] [Related]  

  • 12. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
    Haas I
    Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
    [No Abstract]   [Full Text] [Related]  

  • 13. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 14. [Protein C--a new opening in the treatment of sepsis syndrome].
    Petäjä J; Heikinheimo M
    Duodecim; 2002; 118(12):1217-9. PubMed ID: 12239812
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant human activated protein C.
    Hughes M
    Int J Antimicrob Agents; 2006 Aug; 28(2):90-4. PubMed ID: 16837170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-inflammatory therapy in sepsis].
    Hoffmann JN; Inthorn D; Jauch KW
    Chirurg; 2003 Jun; 74(6):587-8; author reply 588-90. PubMed ID: 12883811
    [No Abstract]   [Full Text] [Related]  

  • 18. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
    Sollet JP; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients with severe sepsis, treated by drotrecogin alfa (activated).
    Laterre PF; Heiselman D
    Am J Surg; 2002 Dec; 184(6A Suppl):S39-46. PubMed ID: 12521616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activated protein C (the impact of PROWESS trial)].
    Iba T; Kidokoro A
    Nihon Rinsho; 2004 Dec; 62(12):2296-300. PubMed ID: 15597799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.